Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Sep 4, 2025, 08:50Monoclonal Antibodies and Heparin-Induced Thrombocytopenia: NEJM Article Shared by Uriel Suárez
-
Sep 4, 2025, 02:53Chokri Ben Lamine on Iron Deficiency Without Anemia (IDWA): Symptoms, Diagnosis, and Management Tips
-
Sep 2, 2025, 13:59No Added Benefit of Surgery Within 72 Hours for Intracerebral Hemorrhage
-
Sep 2, 2025, 13:57DCB Technical Mastery Webinar by SCAI: European Best Practices for Complex Coronary Lesions
-
Sep 2, 2025, 13:51Zack Wheeler’s DVT Diagnosis Highlights Thoracic Outlet Syndrome Risks in Athletes: National Blood Clot Alliance
-
Sep 4, 2025, 07:58Flora Peyvandi: LRRC8 Complexes Control Platelet Function and Arterial Thrombosis
-
Sep 3, 2025, 20:04Aymeric Couturier Shares Recent Studies on Anticoagulation and Atrial Fibrillation in Dialysis
-
Sep 3, 2025, 19:34Evidence Gap in von Willebrand Disease: Commentary from Nathan Connell and Colleagues
-
Sep 3, 2025, 19:18Archil Jaliashvili: Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia
-
Sep 3, 2025, 18:38Dirk Sibbing Shares a Recent ''Excellent Study'' on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 5, 2025, 02:15Abdul Mannan Explains How DOACs Can Confuse Lupus Anticoagulant Testing
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast
-
Sep 3, 2025, 14:11Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
-
Sep 3, 2025, 14:00Jacek Lesinski: The Importance of Whole Blood and Plasma Donation
-
Sep 2, 2025, 14:02King Felipe VI Highlights Global Challenge of Cardiovascular Health at ESC Congress 2025